Dose Optimization Study of Idelalisib in Follicular Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 240
Summary
- Conditions
- Follicular Lymphoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: As of protocol amendment 5, the Idelalisib 100 mg arm is closed to enrollment.Masking: None (Open Label)Masking Description: Double-blind: Prior to protocol amendment 5; Open-label: Participants enrolled as of protocol amendment 5Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02536300
- Collaborators
- Not Provided
- Investigators
- Study Director: Gilead Study Director Gilead Sciences
Get Well Soon